Literature DB >> 20458563

Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma.

Hiroyuki Takamatsu1, Takeshi Yamashita, Takeharu Kotani, Aiko Sawazaki, Hirokazu Okumura, Shinji Nakao.   

Abstract

A 79-year-old female patient with multiple myeloma who had no prior cardiac disease history developed an acute myocardial infarction on day 5 after receiving bortezomib and dexamethasone (BD). After treatment of coronary stenoses by stents, she received another course of BD therapy and developed angina pectoris on day 5 after the therapy. Bortezomib's antitumor effect is due to the inhibition of proteasome activity. This inhibition may increase endothelial progenitor cell apoptosis and decrease endothelial nitric oxide synthase/nitric oxide (eNOS/NO), thus leading to coronary spasm. It is, therefore, important to carefully monitor patients being treated with bortezomib for the potential occurrence of ischemic heart disease.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20458563     DOI： 10.1007/s12185-010-0586-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


  22 in total

1.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

2.  Unexpected cardiotoxicity in haematological bortezomib treated patients.

Authors:  Orciuolo Enrico; Buda Gabriele; Cecconi Nadia; Galimberti Sara; Versari Daniele; Cervetti Giulia; Salvetti Antonio; Petrini Mario
Journal:  Br J Haematol       Date:  2007-06-11       Impact factor: 6.998

3.  High dose dexamethasone increases circulating P-selectin and von Willebrand factor levels in healthy men.

Authors:  Bernd Jilma; Tuende Cvitko; Astrid Winter-Fabry; Karin Petroczi; Peter Quehenberger; Andrew D Blann
Journal:  Thromb Haemost       Date:  2005-10       Impact factor: 5.249

4.  Weekly bortezomib/methylprednisolone is effective and well tolerated in relapsed multiple myeloma.

Authors:  Attaya Suvannasankha; Gina G Smith; Beth E Juliar; Rafat Abonour
Journal:  Clin Lymphoma Myeloma       Date:  2006-09

5.  T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm.

Authors:  M Nakayama; H Yasue; M Yoshimura; Y Shimasaki; K Kugiyama; H Ogawa; T Motoyama; Y Saito; Y Ogawa; Y Miyamoto; K Nakao
Journal:  Circulation       Date:  1999-06-08       Impact factor: 29.690

6.  Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan.

Authors:  M Wada; H Mizoguchi; S I Kuriya; H Taguchi; T Kawamura; I Maekawa; C Shimazaki; Y Sato; Y Niho; T Miyazaki; A Shibata; T Kitani; N Hamajima; R Ohno
Journal:  Br J Haematol       Date:  2000-06       Impact factor: 6.998

Review 7.  Vessel wall apoptosis and atherosclerotic plaque instability.

Authors:  M M Kavurma; R Bhindi; H C Lowe; C Chesterman; L M Khachigian
Journal:  J Thromb Haemost       Date:  2005-03       Impact factor: 5.824

Review 8.  Clinical update: proteasome inhibitors in hematologic malignancies.

Authors:  Paul Richardson
Journal:  Cancer Treat Rev       Date:  2003-05       Impact factor: 12.111

9.  Diagnostic performance of coronary angiography by 64-row CT.

Authors:  Julie M Miller; Carlos E Rochitte; Marc Dewey; Armin Arbab-Zadeh; Hiroyuki Niinuma; Ilan Gottlieb; Narinder Paul; Melvin E Clouse; Edward P Shapiro; John Hoe; Albert C Lardo; David E Bush; Albert de Roos; Christopher Cox; Jeffery Brinker; João A C Lima
Journal:  N Engl J Med       Date:  2008-11-27       Impact factor: 91.245

10.  Involvement of the proteasome in activation of endothelial nitric oxide synthase.

Authors:  Roland Govers; Petra de Bree; Ton J Rabelink
Journal:  Life Sci       Date:  2003-09-12       Impact factor: 5.037
View more
  16 in total

1.  Sustained improvement in cardiac function with persistent amyloid deposition in a patient with multiple myeloma-associated cardiac amyloidosis treated with bortezomib.

Authors:  Hiroya Tamaki; Yoshiro Naito; Masaaki Lee-Kawabata; Yuki Taniguchi; Hiroyuki Hao; Seiichi Hirota; Seiki Hasegawa; Tohru Masuyama; Hiroyasu Ogawa
Journal:  Int J Hematol       Date:  2010-10-27       Impact factor: 2.490

Review 2.  Chemotherapeutic Agents and the Risk of Ischemia and Arterial Thrombosis.

Authors:  Saamir A Hassan; Nicolas Palaskas; Peter Kim; Cezar Iliescu; Juan Lopez-Mattei; Elie Mouhayar; Rohit Mougdil; Kara Thompson; Jose Banchs; Syed Wamique Yusuf
Journal:  Curr Atheroscler Rep       Date:  2018-02-08       Impact factor: 5.113

3.  Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.

Authors:  Kristine M Wadosky; Luge Li; Jessica E Rodríguez; Jin-Na Min; Dan Bogan; Jason Gonzalez; Cam Patterson; Joe N Kornegay; Monte Willis
Journal:  Muscle Nerve       Date:  2011-08-08       Impact factor: 3.217

Review 4.  Cardiovascular Complications of Multiple Myeloma Treatment: Evaluation, Management, and Prevention.

Authors:  Dae Hyun Lee; Michael G Fradley
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-03-06

Review 5.  Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.

Authors:  Oliver Drews; Heinrich Taegtmeyer
Journal:  Antioxid Redox Signal       Date:  2014-10-01       Impact factor: 8.401

6.  A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Authors:  Jacob P Laubach; Javid J Moslehi; Sanjeev A Francis; Jesús F San Miguel; Pieter Sonneveld; Robert Z Orlowski; Philippe Moreau; Laura Rosiñol; Edward A Faber; Peter Voorhees; Maria-Victoria Mateos; Loreta Marquez; Huaibao Feng; Avinash Desai; Helgi van de Velde; Jennifer Elliott; Hongliang Shi; Edward Dow; Nishith Jobanputra; Dixie-Lee Esseltine; Liviu Niculescu; Kenneth C Anderson; Sagar Lonial; Paul G Richardson
Journal:  Br J Haematol       Date:  2017-05-03       Impact factor: 6.998

7.  Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.

Authors:  Ajai Chari; Daher Hajje
Journal:  BMC Cancer       Date:  2014-12-04       Impact factor: 4.430

Review 8.  The ubiquitin proteasome system and myocardial ischemia.

Authors:  Justine Calise; Saul R Powell
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-07       Impact factor: 4.733

9.  Bortezomib-Induced Cardiac Tamponade in a 49-Year-Old Man.

Authors:  Taylor Burkhart; Matthew Cody Lee Keith; Carrie Ann Geisberg Lenneman; Rajeev Ruben Fernando
Journal:  Tex Heart Inst J       Date:  2018-08-01

Review 10.  Challenges and Management of Acute Coronary Syndrome in Cancer Patients.

Authors:  Isabela Bispo Santos da Silva Costa; Fernanda Thereza de Almeida Andrade; Diego Carter; Vinicius B Seleme; Maycon Santos Costa; Carlos M Campos; Ludhmila Abrahão Hajjar
Journal:  Front Cardiovasc Med       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.